CBD epilepsy drug under Real-World watch for rare seizure disorders
NCT ID NCT05485831
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows about 111 people with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex who are taking Epidyolex (a CBD oral solution) for seizures. Researchers track how many stay on the drug for a year and how many seizure-free days they have. It's an observational study, meaning doctors prescribe the drug as usual, and no new treatment is being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epidyolex (cannabidiol, CBD) oral solution
What this could lead to
If successful, this could confirm that CBD helps control seizures in these hard-to-treat epilepsy syndromes, offering a real-world treatment option.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 52 weeks, and CBD may not work for everyone or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Città della Salute PO Molinette
Torino, 10126, Italy
-
AOU Gaetano Martino
Messina, 98124, Italy
-
AOU Maggiore della Carità di Novara
Novara, 28100, Italy
-
AOU di Padova
Padova, 35128, Italy
-
ASST Grande Ospedale metropolitano Niguarda
Milan, 20162, Italy
-
Azienda Ospedaliera Universitaria Federico II
Naples, 80131, Italy
-
Azienda Ospedaliera Universitaria Meyer Neurologia Pediatrica
Florence, 50139, Italy
-
Azienda Ospedaliero Universitaria Sant'Andrea
Roma, 00189, Italy
-
Azienda Ospedaliero Universitaria delle Marche
Torrette, 60126, Italy
-
Centro Regionale Epilessia - ASST Santi Paolo e Carlo
Milan, 20142, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli - IRCCS-NPI
Roma, 00168, Italy
-
IRCCS Ospedale Pediatrico Bambin Gesù
Roma, 00165, Italy
-
Istituto Gaslini Neurologia Pediatrica e Malattie Muscolari
Genova, 16147, Italy
-
NPI AOU Mater Domini Università Magna Graecia
Catanzaro, 88100, Italy
-
Ospedale Casa del sollievo e della sofferenza
San Giovanni Rotondo, 71013, Italy
-
Policlinico Sant'Orsola di Bologna
Bologna, 40138, Italy
-
Policlinico Tor Vergata
Roma, 00133, Italy
-
Università degli studi "G. D'annunzio" Chieti
Chieti, 66100, Italy